SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (762)12/3/1999 3:19:00 PM
From: Mike McFarland  Read Replies (1) of 4474
 
Despite the fact that the issue is
immune response to that particular
vector... my initial thought back then was
that it should give regulation systems some good
press--the FDA will increasingly demand
Gene Therapy with some measure of control.
ARGENT and the Baylor/Valentis geneswitch
should have showed up somewhere in the
popular press by now, but maybe next year.

There may have been some extra enthusiasm
on the AAV plays...the Street seems to
understand that this is one of the safer
vectors...but the public certainly does not
have an appreciation for the hybrid Ad/AAV
systems...Heck, words like promoter and
enchancer didn't even show up in my vocabulary
til this past summer--and I don't think I
can use them in a sentence, heheh.

I think there was a short subthread on the
Gene Therapy thread at the time of the death.
That is also about the time the guys on the
Ariad Yahoo thread starting using expressions
like "frought with peril", but that settled
down pretty quick after they shook me out
(not that it was intentional mind you)
and the stock make it's spectacular bottom.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext